C9orf72 — Chromosome 9 Open Reading Frame 72

📖 Wiki Page

gene1149 wordssynced 2026-04-02

C9orf72 (Chromosome 9 Open Reading Frame 72)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">C9orf72 — Chromosome 9 Open Reading Frame 72</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Toxic Species</td>
</tr>
<tr>
<td class="label">RNA toxicity</td>
<td>Sense/antisense foci</td>
</tr>
<tr>
<td class="label">DPR translation</td>
<td>poly-GR, poly-PR</td>
</tr>
<tr>
<td class="label">Loss of function</td>
<td>C9orf72 reduction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als/ftd" style="color:#ef9a9a">ALS/FTD</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">872 edges</a></td>
</tr>
</table>

Overview

...

C9orf72 (Chromosome 9 Open Reading Frame 72)

Overview

[C9orf72](/genes/c9orf72) repeat expansion is the most common known genetic cause of familial [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal dementia](/diseases/frontotemporal-dementia), and a major molecular bridge across the ALS-FTD spectrum.[^1][@singh2026] Pathogenic GGGGCC repeat expansions in the first intron/promoter region drive a mixed loss-of-function and toxic gain-of-function biology involving RNA foci, dipeptide repeat proteins (DPRs), nucleocytoplasmic transport failure, and impaired proteostasis.[@li2026][@kurdi2026][@luong2026]

Genomic Architecture And Pathogenic Expansion

The normal C9orf72 repeat tract is short, while pathogenic alleles contain large expansions (often hundreds to thousands of repeats). Detection strategies include repeat-primed PCR and long-read approaches for difficult borderline alleles.[^1][@russell2026]

Key architecture points:

Locus: chromosome 9p21.2.
Pathogenic element: non-coding GGGGCC repeat expansion.
Inheritance: autosomal dominant with age-dependent penetrance and variable expressivity.

Clinical expression ranges from pure motor neuron disease to behavioral/cognitive syndromes, frequently within one pedigree, reinforcing shared upstream mechanisms.[@singh2026][@inami2026]

Physiologic C9orf72 Function

C9orf72 protein forms a complex with SMCR8 and WDR41 that regulates endolysosomal trafficking and [autophagy](/entities/autophagy) initiation, with additional roles in immune signaling and lysosomal homeostasis.[@huang2026][@jiang2026] In [neurons](/entities/neurons) and myeloid-lineage cells, reduced C9orf72 expression can impair cargo clearance and stress adaptation, sensitizing systems already burdened by repeat toxicity.[@huang2026][@ross2026]

Core Pathogenic Mechanisms

1. RNA Foci Toxicity

Expanded sense and antisense transcripts form nuclear RNA foci that sequester RNA-binding proteins and alter splicing/translation programs.[@li2026][@lian2026] This mechanism can operate early, before frank neuronal loss.

2. RAN Translation And DPR Toxicity

Repeat-associated non-AUG translation produces poly-GA, poly-GR, poly-PR, poly-GP, and poly-PA peptides. Arginine-rich DPRs (GR/PR) disrupt ribosomal function[@jiang2026], phase-separated organelles, and nucleolar biology.[@kurdi2026][^12][^13]

3. Nucleocytoplasmic Transport Defects

C9-related RNA and DPR species interfere with nuclear pore and transport factors, resulting in impaired protein/RNA trafficking and downstream stress responses[@lian2026].[@luong2026][^14]

4. Loss-Of-Function And Immune Dysregulation

Lower C9orf72 expression can independently perturb lysosomal and immune pathways, especially in [microglia](/cell-types/microglia), potentially amplifying neuroinflammatory loops in ALS-FTD[@kurdi2026].[@jiang2026][@ross2026]

Clinical Phenotypes

ALS Phenotype

C9 carriers often present with limb or bulbar ALS, faster decline in subsets, and higher probability of cognitive/behavioral involvement compared with non-carriers.[@inami2026][^15]

FTD Phenotype

Behavioral variant FTD is common, with disinhibition/apathy syndromes and early executive dysfunction. Language variants also occur but are less frequent than in GRN-linked disease.[@singh2026][^15]

Mixed ALS-FTD And Psychiatric Features

The expansion is associated with psychosis and other neuropsychiatric features in a subset of families, emphasizing the need for broad phenotyping in precision trial enrollment.[^16]

Biomarker And Therapeutic-Target Relevance

C9orf72 is one of the best examples of a genetically defined precision-neurology target in neurodegeneration:

Target engagement biomarkers: CSF poly(GP) is used in antisense and small-molecule programs as a pharmacodynamic marker of repeat transcript suppression.[^17]
Fluid progression markers: [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) remains useful for risk/progression enrichment in symptomatic and presymptomatic carriers.[^18]
Multimodal staging: combining genotype, fluid markers, cognition, and MRI network signatures improves power for early-phase studies.[^15][^18]

Therapeutic Landscape

Antisense Oligonucleotides (ASOs)

ASO strategies aim to reduce repeat-containing transcripts and downstream DPR production. Early trials established feasibility and target engagement, while efficacy optimization remains an active area.[^17][^19]

Small-Molecule And RNA-Targeting Approaches

Programs targeting repeat RNA structures, RAN translation, and stress granule dynamics are under development in preclinical and translational pipelines.[@lian2026][^13]

Pathway-Combination Strategies

Because C9 disease combines RNA toxicity, proteostasis failure, and neuroinflammation, combination strategies (repeat suppression plus clearance/inflammation modulation) are biologically plausible and increasingly prioritized.[@jiang2026][@ross2026][^19]

Research Gaps

Better predictors of penetrance and age-at-onset are needed for preventive trial design.
The relative contribution of loss-of-function versus DPR toxicity likely varies by stage and cell type.
Longitudinal human data connecting biomarker shifts to meaningful clinical deltas remain limited.

External Links

[C9orf72 Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/203523)
[C9orf72 - ALS Association](https://www.als.org/)
[C9orf72 Hexanucleotide Repeat Expansion - PubMed](https://pubmed.ncbi.nlm.nih.gov/21944779/)

Brain Atlas Resources

Allen Human Brain Atlas: [Expression data for C9ORF72](https://human.brain-map.org/microarray/search/show?search_term=C9ORF72)
Allen Cell Type Atlas: [Cell type expression data](https://celltype.brain-map.org/)
BrainSpan Atlas: [Developmental transcriptome data](https://www.brainspan.org/)

Pathway Diagram

Mermaid diagram (expand to render)

Disease Mechanism Summary

C9orf72 and 4R Tauopathies

A 2025 study examined whether intermediate C9orf72 repeat expansions represent a genetic risk factor for [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP), [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), corticobasal degeneration (CBD), and atypical parkinsonism [1].

Key Findings

The PROSPECT study analyzed 626 clinical cases (366 PSP, 130 CBS, 53 atypical parkinsonism) plus 77 pathologically confirmed CBD cases:

No significant difference in mean or largest allele size between affected patient groups and controls
No significant difference in frequency of intermediate expansions between patients and controls
No relationship found between repeat length and age at onset, disability level, or survival

Conclusion

Intermediate C9orf72 repeat expansions do not appear to be a genetic risk factor for PSP, CBS, CBD, or atypical parkinsonism. Pathogenic hexanucleotide repeat expansions remain the most common genetic cause of [frontotemporal dementia](/diseases/frontotemporal-dementia) and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), but intermediate repeats do not contribute to these atypical Parkinsonian disorders.

References

[Singh J et al, PAICS mediates DNA damage and cerebellar neuronal loss in C9orf72 amyotrophic lateral sclerosis (2026)](https://pubmed.ncbi.nlm.nih.gov/41810938/)

[Li Y et al, Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS (2026)](https://pubmed.ncbi.nlm.nih.gov/41763422/)

[Kurdi MA et al, Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review (2026)](https://pubmed.ncbi.nlm.nih.gov/41752118/)

[Luong DT et al, PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice (2026)](https://pubmed.ncbi.nlm.nih.gov/41751955/)

[Russell KA et al, Intrathecal (G(4)C(2))(149) delivery in C9orf72-deficient mice yields mild motor dysfunction and ALS/FTD pathological hallmarks (2026)](https://pubmed.ncbi.nlm.nih.gov/41727102/)

[Inami S et al, Increased neuronal activity restores circadian function in Drosophila models of C9orf72-ALS/FTD (2026)](https://pubmed.ncbi.nlm.nih.gov/41717003/)

[Huang S et al, Behavioral Variant Frontotemporal Dementia With C9orf72 Intermediate Repeat Expansion: A case report (2026)](https://pubmed.ncbi.nlm.nih.gov/41665027/)

[Jiang X et al, Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes (2026)](https://pubmed.ncbi.nlm.nih.gov/41643021/)

[Ross D et al, Thermally activated history-dependent homogenization of G-quadruplexes in an ALS/FTD-associated gene (2026)](https://pubmed.ncbi.nlm.nih.gov/41640102/)

[Lian L et al, Aberrant CDK4/6-driven cell-cycle reentry drives neuronal loss and defines a therapeutic target in C9orf72 ALS/FTD (2026)](https://pubmed.ncbi.nlm.nih.gov/41623487/)

Pathway Diagram

The following diagram shows the key molecular relationships involving C9orf72 — Chromosome 9 Open Reading Frame 72 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Associated Diseases

ALS — associated with

[View disease page](/diseases/als)

amyotrophic lateral sclerosis — causes

[View disease page](/diseases/amyotrophic-lateral-sclerosis)

Amyotrophic Lateral Sclerosis — associated with

[View disease page](/diseases/amyotrophic-lateral-sclerosis)

frontotemporal dementia — causes

[View disease page](/diseases/frontotemporal-dementia)

Frontotemporal dementia — causes

[View disease page](/diseases/frontotemporal-dementia)

📖 View canonical wiki page →

C9orf72 — Chromosome 9 Open Reading Frame 72

C9orf72 (Chromosome 9 Open Reading Frame 72)

Overview

C9orf72 (Chromosome 9 Open Reading Frame 72)

Overview

Genomic Architecture And Pathogenic Expansion

Physiologic C9orf72 Function

Core Pathogenic Mechanisms

1. RNA Foci Toxicity

2. RAN Translation And DPR Toxicity

3. Nucleocytoplasmic Transport Defects

4. Loss-Of-Function And Immune Dysregulation

Clinical Phenotypes

ALS Phenotype

FTD Phenotype

Mixed ALS-FTD And Psychiatric Features

Biomarker And Therapeutic-Target Relevance

Therapeutic Landscape

Antisense Oligonucleotides (ASOs)

Small-Molecule And RNA-Targeting Approaches

Pathway-Combination Strategies

Research Gaps

See Also

External Links

Brain Atlas Resources

Pathway Diagram

Disease Mechanism Summary

C9orf72 and 4R Tauopathies

Key Findings

Conclusion

References

Pathway Diagram

Associated Diseases